2 min read
For pharmaceutical companies planning to enter the United Arab Emirates (UAE), understanding the role of the Ministry of Health and Prevention (MOHAP) and the role of the Emirates Drug Establishment (EDE) is essential.
The Ministry of Health and Prevention (MOHAP) is the federal authority responsible for public health policy, healthcare regulation, disease prevention, and the oversight of healthcare services across the UAE.
Understanding MOHAP’s Role
MOHAP develops healthcare policies and oversees public health initiatives across the UAE. MOHAP also regulates healthcare professionals, ensures compliance with health standards, and manages health information systems to enhance the efficiency of the health sector. Additionally, it plays a significant role in public wellness and epidemiological management, contributing to the overall quality of healthcare services.
Key Responsibilities of MOHAP
- Healthcare Regulation and Licensing
- Public Health Policy and Disease Prevention
- Healthcare Service Delivery
- Digital Health and Innovation
- Coordination with Emirate-Level Authorities
- Pharmaceutical and Medical Product Oversight through EDE
The Emirates Drug Establishment (EDE) is the UAE’s independent regulatory body responsible for overseeing the pharmaceutical and medical device industries, established on 29th September 2023.
Understanding EDE’s Role
The EDE plays a crucial role in transforming the healthcare sector in the UAE. It is the only
federal authority responsible for regulating all medical and pharmaceutical products,
including Pharmaceuticals, Medical Devices, Cosmetics, Dietary Supplements, Genetically Modified Organisms (GMOs), Fertilizers and Pesticides.
The establishment of the EDE marks a significant shift in the regulatory oversight, previously managed by MOHAP. This change aims to enhance the UAE’s position as a global leader in medical technology and pharmaceuticals.
Key Responsibilities of EDE
Licensing of Pharmaceutical Establishments
EDE oversees licensing requirements for manufacturers, distributors, medical warehouses, and other pharmaceutical entities.
Medicinal Product Approval
Pharmaceutical products must receive regulatory approval before they can be imported, marketed, or distributed in the UAE. EDE assesses product documentation to ensure compliance with applicable standards. EDE oversees the manufacturing, importation, distribution and trade of human and veterinary medicines.
Drug Safety Monitoring & Pharmacovigilance
EDE supports pharmacovigilance activities by monitoring adverse events, updating Risk Management Plan and System, and ensuring continued product safety after approval.
Pricing Review
EDE applies pricing regulations on medicines before receiving commercialization (MA) approval.
Advertising and Labeling Compliance
Packaging materials, promotional content, and product labels must comply with EDE / UAE regulations.
Why It Matters for Pharmaceutical Companies
The UAE continues to grow as a strategic pharmaceutical market in the Middle East. Companies often face challenges such as:
- Navigating evolving regulations
- Managing local representation requirements
- Preparing compliant submissions
- Handling post-approval obligations
- Maintaining long-term compliance
A proactive regulatory strategy helps reduce delays and improve market entry timelines.
Final Thoughts
Understanding EDE’s role helps pharmaceutical companies build stronger regulatory strategies for successful UAE market entry.
Looking to streamline your UAE regulatory journey? Freyr supports pharmaceutical companies with regulatory strategy, dossier preparation, submissions, lifecycle management, labeling review, and market access support to help accelerate approvals.